Back FOR IMMEDIATE RELEASE BioSeek and Dynavax Technologies Enter into Drug Discovery Collaboration BioSeek's BioMAP technology to be applied to define activity of novel family of TNF-alpha inhibitors Burlingame, California June 24, 2003 - BioSeek, Inc. today announced that it has entered into a collaboration with Dynavax Technologies, Berkeley, CA., in which BioSeek will apply its BioMAPTM human cell-based model systems technology to analyze and characterize the activity of novel compounds known as thiazolopyrimidines. Dynavax is developing these proprietary compounds for treatment of chronic inflammatory diseases. The terms of the agreement include milestone payments to BioSeek based on achievement of technical and commercial milestones and royalties on sales of products resulting from the collaboration. Detailed financial terms were not disclosed. "We are excited to be working with the innovative team at Dynavax to advance a program with great potential in treating inflammatory diseases," commented Peter Staple, chief executive officer of BioSeek. "BioMAP technology is a powerful resource for rapidly deciphering the functional activity of drug candidates in complex disease environments, and this collaboration provides an excellent opportunity for its application." "We are impressed with the capabilities of BioSeek's technologies," said Dino Dina, M.D. president and chief executive officer of Dynavax Technologies. "We look forward to working with BioSeek to gain important insights into the biological functions of our compounds in this collaboration," BioMAP technology is a high-throughput human systems biology platform that enables rapid determination of efficacy, side effects and mechanism of action of drug candidates and identification of "first in class" drugs. BioSeek is applying BioMAP for drug discovery in major therapeutic areas including inflammatory and autoimmune diseases, cardiovascular disease and cancer. The BioMAP approach provides rapid, in-depth drug- and gene-effect information from highly disease relevant model cell systems with applications throughout the drug discovery and development process. The BioMAP platform comprises primary human cell-based disease models forinflammatory and autoimmune disease, cardiovascular disease and cancer. Combinations of primary human cells are assayed in proprietary formats with multiple disease-associated regulatory pathways activated in concert. BioMAP model systems are designed to reflect human disease pathology and are validated for their ability to detect and distinguish the effects of approved and investigational human therapeutics. Applications for BioMAP technology have been demonstrated for: selection and prioritization of drug leads; compound mechanism of action; side effect profiling; and surrogate marker identification. About BioSeek BioSeek, the human systems biology company, is transforming and accelerating the drug discovery process by applying its proprietary high-throughput human disease systems to identify and characterize potential new pharmaceutical products. The Company's core technology addresses the central challenge of postgenomic drug discovery: the need to integrate biology and biological function analyses into the drug development process. BioSeek's unique human biosystems approach allows the Company to identify and prioritize the most promising genomic targets and drug candidates very early in the drug discovery process. For more information, please e-mail BioSeek directly. About Dynavax Dynavax Technologies is a privately held biopharmaceutical company developing innovative products to treat allergy, inflammation-mediated diseases, infectious diseases, and cancer. The company's lead products are based on ImmunoStimulatory Sequences (ISS), short DNA sequences that enhance the ability of the immune system to fight disease and prevent inflammation. Dynavax's two most advanced products include an ISS-based next-generation vaccine for the prevention of hepatitis B, currently in pivotal Phase II clinical trials, and AIC, now in late Phase II clinical testing for the treatment of ragweed allergy. Dynavax also has an oral TNF-alpha synthesis inhibitor in preclinical development for rheumatoid arthritis. A company profile is available at the Dynavax website, www.dynavax.com .